Dipna Pharmachem MD, chairman, board of directors and AGM
BSE: 543594Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹3.93.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹10 Cr3,953rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day.
- 18,000
Dipna Pharmachem board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorKeyur Dipakkuamr Shah
4 directors2 independent1 executive1 non-executive
- Keyur Dipakkuamr Shah · Chairperson and managing directorExecutive · joined May 2022 · 1 listed board
- Dipna Keyur ShahNon-executive · joined Jul 2011 · 1 listed board · 2 committee seats
- Jitendra Pradipbhai ParmarIndependent · joined May 2026 · 1 month as independent · 2 listed boards · 2 as independent · 4 committee seats, 2 as chair
- Manish Shrichand BachaniIndependent · joined May 2026 · 1 month as independent · 6 listed boards · 6 as independent · 9 committee seats, 2 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
2 directors who left
- Nandish Shaileshbhai Jani, left 10 Jun 2026: Others
- Parin Shirishkumar Bhavsar, left 12 May 2026: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 11 May 20264 of 4 present2 independent · 18 days in between
- 22 Apr 20264 of 4 present2 independent · 27 days in between
- 25 Mar 20264 of 4 present2 independent
Audit Committee
Chair Jitendra Pradipbhai Parmar
Manish Shrichand Bachani, Dipna Keyur Shah
- 22 Apr 20263 of 3 present2 independent · 27 days in between
- 25 Mar 20263 of 3 present2 independent
Nomination and remuneration committee
Chair Jitendra Pradipbhai Parmar
Manish Shrichand Bachani, Dipna Keyur Shah
- 11 May 20263 of 3 present2 independent · 18 days in between
Stakeholders Relationship Committee
Chair Jitendra Pradipbhai Parmar
Manish Shrichand Bachani, Dipna Keyur Shah
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Devadiya & AssociatesPeer-review certificate valid to May 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Fines and tax disputes
Reported in the filing for the quarter to Jun 2026.
- Fine or penaltyGST DepartmentSince 19 Jan 2026
Search intiated on date 19-01-2026
Allegation of Fake utilization of ITC - Fine or penaltyIncome Tax DepartmentSince 23 Feb 2026
We have filed an appeal before CIT(A) against such Order passed on dated 23-02-2026
Various disputed additions as per the Assessment Order like Unxplained Credit etc. - Tax disputeGST DepartmentSince 19 Jan 2026OngoingAt the filing before: SCN awaited
- Tax disputeIncome Tax DepartmentSince 23 Feb 2026OngoingAt the filing before: Date of hearing not received
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- Yes
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesFeb 2025 | 2.20 | To meet Working Capital Requirements | 56.80 | 15.85 | No |
| Preferential IssuesFeb 2025 | 2.20 | General Corporate Purpose | 18.93 | 5.28 | No |